WO2013007704A3 - Novel sdf-1-based glycosaminoglycan antagonist and methods of using same - Google Patents

Novel sdf-1-based glycosaminoglycan antagonist and methods of using same Download PDF

Info

Publication number
WO2013007704A3
WO2013007704A3 PCT/EP2012/063438 EP2012063438W WO2013007704A3 WO 2013007704 A3 WO2013007704 A3 WO 2013007704A3 EP 2012063438 W EP2012063438 W EP 2012063438W WO 2013007704 A3 WO2013007704 A3 WO 2013007704A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
sdf
methods
antagonist
same
Prior art date
Application number
PCT/EP2012/063438
Other languages
French (fr)
Other versions
WO2013007704A2 (en
Inventor
Andreas Kungl
Martin Uwe TRINKER
Jason Slingsby
Original Assignee
Protaffin Biotechnologie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protaffin Biotechnologie Ag filed Critical Protaffin Biotechnologie Ag
Priority to EP12733152.8A priority Critical patent/EP2729487A2/en
Publication of WO2013007704A2 publication Critical patent/WO2013007704A2/en
Publication of WO2013007704A3 publication Critical patent/WO2013007704A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to novel SDF-1 mutant polypeptides with increased GAG binding affinity and reduced GPCR activity compared to wild type SDF-1 protein wherein said SDF-1 polypeptide is modified in a structure-conserving way by replacing glutamine at position 60 by a basic or electron donating amino acid and by replacing at least one additional amino acid at position 29, 39, 49, 67 and/or 68 according to the numbering of SEQ ID NO 1 by at least one basic and/or electron donating amino acid and wherein at least one amino acid of the first 1 to 10 amino acids of the N-terminal region of the wild type SDF-1 polypeptide is modified by addition, deletion and/or replacement of at least one amino acid and methods for producing these mutants and to their use for preparing medicaments for the treatment of cancer.
PCT/EP2012/063438 2011-07-08 2012-07-09 Novel sdf-1-based glycosaminoglycan antagonist and methods of using same WO2013007704A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12733152.8A EP2729487A2 (en) 2011-07-08 2012-07-09 Novel sdf-1-based glycosaminoglycan antagonist and methods of using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11173228 2011-07-08
EP11173228.5 2011-07-08

Publications (2)

Publication Number Publication Date
WO2013007704A2 WO2013007704A2 (en) 2013-01-17
WO2013007704A3 true WO2013007704A3 (en) 2013-03-07

Family

ID=46466571

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/063438 WO2013007704A2 (en) 2011-07-08 2012-07-09 Novel sdf-1-based glycosaminoglycan antagonist and methods of using same

Country Status (2)

Country Link
EP (1) EP2729487A2 (en)
WO (1) WO2013007704A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054285A1 (en) * 2003-12-04 2005-06-16 Protaffin Biotechnologie Ag Gag binding proteins
WO2008074047A1 (en) * 2006-12-20 2008-06-26 Protaffin Biotechnologie Ag Chemokine-chaperone fusion proteins
WO2009053064A1 (en) * 2007-10-24 2009-04-30 Protaffin Biotechnologie Ag Sdf-1-based glycosaminoglycan antagonists and methods of using same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60103052T2 (en) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver USE OF CXCR4 ANTAGONISTS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES
WO2010122176A1 (en) 2009-04-24 2010-10-28 Protaffin Biotechnologie Ag A method to identify glycosaminoglycan (gag) binding sites in proteins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054285A1 (en) * 2003-12-04 2005-06-16 Protaffin Biotechnologie Ag Gag binding proteins
WO2008074047A1 (en) * 2006-12-20 2008-06-26 Protaffin Biotechnologie Ag Chemokine-chaperone fusion proteins
WO2009053064A1 (en) * 2007-10-24 2009-04-30 Protaffin Biotechnologie Ag Sdf-1-based glycosaminoglycan antagonists and methods of using same

Also Published As

Publication number Publication date
WO2013007704A2 (en) 2013-01-17
EP2729487A2 (en) 2014-05-14

Similar Documents

Publication Publication Date Title
NZ630484A (en) Compositions and methods for treatment of metabolic disorders and diseases
MY160995A (en) Polypeptides with permease activity
MX2014003677A (en) Fusion proteins for treating metabolic disorders.
EA201200398A1 (en) POLYPEPTIDES WITH OXIDOCUTAZA ACTIVITY AND THEIR APPLICATION
MX2012008780A (en) Methods and compositions using fgf23 fusion polypeptides.
NZ603016A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
NZ609216A (en) Anticancer fusion protein
WO2014118360A3 (en) Carbohydrate degrading polypeptide and uses thereof
MY160897A (en) Polypeptide having or assisting in carbohydrate material degrading activity and uses thereof
IN2012DN02981A (en)
NZ590050A (en) Fgf21 mutants and uses thereof
NZ595500A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
MX360211B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
UA93669C2 (en) Process for producing polypeptide mixtures using hydrogenolysis
NZ628625A (en) Polypeptides binding to human complement c5
NZ586430A (en) Mutant forms of streptolysin o (slo)
WO2012074277A3 (en) Novel hybrid promoter and recombinant vector comprising the same
NZ597306A (en) Mesenchymal stem cell differentiation
NZ742660A (en) Variants of chymosin with improved milk-clotting properties
MX353074B (en) Novel prongf mutants and uses thereof in the production of beta-ngf.
EP2589658A4 (en) Partial region polypeptide of reic/dkk-3 protein
MX365095B (en) Methods and compositions for increasing sialic acid production and treating sialic related disease conditions.
UA106458C2 (en) Sulfonylurea-responsive repressor protein
NZ562436A (en) Toll-like receptor 14 (TLR14) and use thereof
NZ703093A (en) Purification of iduronate-2-sulfatase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12733152

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012733152

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12733152

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE